Introduction
============

Intracerebral hemorrhage (ICH) occurs at an annual incidence rate of 15 to 19 per 100,000 \[[@B1]\]. ICH accounts for approximately 15% of acute strokes in the United States and 22--35% in Asian populations \[[@B2]-[@B5]\]. ICH can be a devastating type of stroke, and the 30-day case mortality rate of ICH is 40% to 50%. \[[@B2],[@B6]\]. A pooled prospective study found that the risk factors for ICH were older age, African-American ethnicity, hypertension, lower LDL-C, and lower triglycerides \[[@B7]\]. ICH has been shown to have important genetic and environmental risk factors.

Apolipoprotein E (APOE) gene, located on the long arm of chromosome 19, codes for a 299-amino acid protein (apoE). ApoE is a polymorphic glycoprotein involved in cholesterol transport and cell membrane maintenance and repair \[[@B8],[@B9]\]. *APOE* has three common alleles: epsilon 2 (ϵ2), ϵ3, and ϵ4 that encode the three major isoforms of apoE: E2, E3, and E4, which performs isoform-dependent neurotrophic and antioxidant functions \[[@B8],[@B10]-[@B12]\]. Each person has 2 alleles that together compose that person's *APOE* genotype (e.g., ϵ2/ϵ3 or ϵ3/ϵ3). *APOE* is one of the most widely studied genes in vascular and neurodegenerative diseases \[[@B13]\].

Recently, some studies have been conducted to clarify the association between *APOE* gene polymorphisms and the risk of ICH \[[@B14]-[@B24]\]. However, previous studies investigating the association have reported conflicting results \[[@B25],[@B26]\]. We here performed a meta-analysis based on the evidence currently available from the literature to make a more precise estimation of this relationship.

Materials and methods
=====================

Literature search strategy
--------------------------

We used a detailed electronic search strategy in Medline and Embase from 1950 to the end of March 2013. Two authors independently searched the databases using following key words in all relevant combinations: 'cerebral' or 'intracerebral' or 'intracranial', 'hemorrhage', 'apolipoprotein E\*' or 'ApoE\*', 'polymorphism' or 'allele' or 'genotype' or 'variant'. The search was conducted without limitation on language. The reference lists of all retrieved publications were scrutinized for additional studies. If studies had partially overlapping subjects, the smaller dataset was excluded. If necessary, we attempted to contact the principal investigators of retrieved articles to require additional data.

Inclusion and exclusion criteria
--------------------------------

The following criteria were used to include published studies: (i) independent epidemiological studies (for humans only); (ii) a clear description of *APOE* allele in ICH cases and controls; (iii) sufficient allele data were presented to calculate the odds ratio (OR) and 95% confidence interval (CI); Major reasons for exclusion of studies were (i) no control; (ii) not an original paper (e.g. review or letter etc.); (iii) duplicate publications.

Data extraction
---------------

Data were extracted by two authors independently, and disagreements were resolved by consensus. When a study did not explicitly report one or more of the requested data, we contacted the author of the study for additional details. The following data were extracted: the last name of the first author, publication year, country, study design, genotyping method, sample size and the results of studies.

Statistical analysis
--------------------

All analyses were performed using STATA 11.0 (Stata-Corp LP, College Station, TX, USA). The Mantel-Haenszel method for fixed effects and the Der-Simonian-Laird method for random effects were used to estimate pooled OR and corresponding 95% CI. Meta-analysis heterogeneity was quantified by computing Cochrane's Q and corresponding *P*-value and I^2^ (percent of effect size attributable to heterogeneity). We used fixed-effects methods if the result of the Q test was not significant. Otherwise, we calculated pooled estimates and confidence intervals assuming a random-effects model. Also, subgroup analyses were performed on the basis of race. In this study, *P* \< 0.05 was considered statistically significant. Publication bias was assessed by visual inspection of funnel plots, the Begg\'s rank correlation method and the Egger\'s weighted regression method.

Results
=======

Study characteristics
---------------------

Characteristics of studies included in the meta-analysis are summarized in Table [1](#T1){ref-type="table"}. Our initial search identified 108 studies according to the search words. Through the step of screening the title, abstracts, 85 articles were excluded, leaving 23 articles for full publication review. Of these, 12 were excluded \[[@B25]-[@B36]\]. Finally, a total of 11 studies were included in our meta-analysis \[[@B14]-[@B24]\], which included 1,238 ICH cases and 3,575 controls. Of those, three studies were population-based case--control studies, and eight studies were hospital-based case--control studies. Studies were conducted in USA, United Kingdom, Portugal, Japan, India and China. The frequencies of apolipoprotein E alleles of studies included in the meta-analysis were shown in Table [2](#T2){ref-type="table"}.

###### 

Characteristics of studies included in the meta-analysis

  **Study (author, year)**   **Design**   **Study period**   **Population (country)**      **Genotyping method**   **No. of cases**   **No. of controls**
  -------------------------- ------------ ------------------ ----------------------------- ----------------------- ------------------ ---------------------
  Nakata 1997                HCC          1992-1995          Asians (Japan)                PCR                     38                 38
  McCarron 1998              HCC          DNR                Caucasians (United Kingdom)   PCR                     71                 406
  Garcia 1999                PCC          DNR                Caucasians (Portugal)         PCR-RFLP                48                 173
  Kokubo 2000                PCC          1997-1999          Asians (Japan)                PCR-RFLP                84                 1126
  Catto 2000                 HCC          1997               Caucasians (United Kingdom)   PCR                     60                 289
  Chowdhury 2001             HCC          1998-1999          Asians (Japan)                PCR-RFLP                80                 190
  Woo 2002                   PCC          1997-2000          Caucasians (USA)              PCR                     188                366
  Woo 2005                   HCC          1997-2002          Caucasians (USA)              TaqMan                  172                339
  Chen 2009                  HCC          DNR                Asians (China)                PCR                     217                280
  Zhang 2012                 HCC          2008-2010          Asians (China)                PCR-RFLP                180                180
  Misra 2012                 HCC          DNR                Asians (India)                PCR                     100                188

*Abbreviations*: *HCC* Hospital-based case--control, *PCC* Population-based case--control, *DNR* Data not reported, *PCR* Polymerase chain reaction, *RFLP* Restriction fragment length polymorphism.

###### 

Frequencies of apolipoprotein E alleles of studies included in the meta-analysis

  **Study (author, year)**   **ϵ2 of cases**   **ϵ3 of cases**   **ϵ4 of cases**   **ϵ2 of controls**   **ϵ3 of controls**   **ϵ4 of controls**
  -------------------------- ----------------- ----------------- ----------------- -------------------- -------------------- --------------------
  Nakata 1997                3                 32                3                 2                    32                   4
  McCarron 1998              18                89                35                66                   599                  147
  Garcia 1999                4                 84                8                 14                   298                  34
  Kokubo 2000                14                131               23                103                  1913                 236
  Catto 2000                 5                 95                20                44                   446                  88
  Chowdhury 2001             2                 146               12                13                   333                  34
  Woo 2002                   39                96                53                64                   206                  96
  Woo 2005                   15                118               39                25                   266                  48
  Chen 2009                  33                359               42                44                   479                  37
  Zhang 2012                 26                280               54                26                   314                  20
  Misra 2012                 7                 183               10                15                   343                  18

Quantitative synthesis
----------------------

The combined results based on all studies showed that ICH cases had a significantly higher frequency of *APOE* ϵ4 allele (OR= 1.42, 95% CI= 1.21,1.67, *P*\<0.001) (Figure [1](#F1){ref-type="fig"}) (Table [3](#T3){ref-type="table"}). In the subgroup analysis by race, we also found that ICH cases had a significantly higher frequency of *APOE* ϵ4 allele in Asians (OR= 1.52, 95% CI= 1.20,1.93, *P*\<0.001) and in Caucasians (OR= 1.34, 95% CI= 1.07,1.66, *P*=0.009) (Figure [1](#F1){ref-type="fig"}) (Table [3](#T3){ref-type="table"}). There was no significant relationship between *APOE* ϵ2 allele and the risk of ICH (Figure [2](#F2){ref-type="fig"}) (Table [3](#T3){ref-type="table"}).

![**Meta-analysis of*APOE*alleles and ICH (ϵ4 versus ϵ3).**](1476-511X-13-47-1){#F1}

###### 

Meta-analysis of apolipoprotein E alleles and intracerebral hemorrhage risk

               **No. of studies**   **OR (95% CI)**    ***P*of OR**   ***P*of heterogeneity**   **OR (95% CI)**    ***P*of OR**   ***P*of heterogeneity**
  ------------ -------------------- ------------------ -------------- ------------------------- ------------------ -------------- -------------------------
  All          11                   1.42 (1.21,1.67)   \<0.001        0.09                      1.18 (0.96,1.44)   0.11           0.29
  Asians       6                    1.52 (1.20,1.93)   \<0.001        0.05                      1.11 (0.83,1.47)   0.47           0.25
  Caucasians   5                    1.34 (1.07,1.66)   0.009          0.32                      1.26 (0.94,1.68)   0.12           0.28

*Abbreviations*: *OR* Odds ratio, *CI* Confidence interval.

![**Meta-analysis of*APOE*alleles and ICH (ϵ2 versus ϵ3).**](1476-511X-13-47-2){#F2}

Heterogeneity analysis and publication bias
-------------------------------------------

Statistical heterogeneity was not found among studies in overall comparisons by using the Q statistic (Table [3](#T3){ref-type="table"}). Publication bias was not found by the Begg\'s rank correlation method (Figure [3](#F3){ref-type="fig"}) or Egger weighted regression method (Figure [4](#F4){ref-type="fig"}).

![**Begg's publication bias plot of*APOE*alleles and ICH.**](1476-511X-13-47-3){#F3}

![**Egger's publication bias plot of*APOE*alleles and ICH.**](1476-511X-13-47-4){#F4}

Discussion
==========

There is evidence for a role of genetic factors in the development of ICH. Studies investigating the association between genetic polymorphisms and ICH risk are being reported with rapidly increasing frequency. Endoglin gene polymorphism was a risk factor for sporadic ICH \[[@B37]\]. A comparative study that angiotensin converting enzyme (ACE) gene DD homozygosity of the I/D polymorphism in intron 16 is an independent risk factor for ICH in a Polish population \[[@B38]\]. A case--control study suggested that the beta1-tubulin Q43P polymorphism could be associated with ICH in men from southern Spain \[[@B39]\]. A population-based prospective nested case--control study found that estrogen receptor alpha gene polymorphisms were associated with first-ever ICH, particularly in combination with hypertension \[[@B40]\]. A case--control study found that glutathione peroxidase 1 C593T polymorphism was associated with lobar ICH in a Polish population \[[@B41]\]. A case--control study suggested that the rs2228048 of *TGFBR2* gene may be associated with development of ICH in Korean population \[[@B42]\]. A study suggested that the rs17222919 of *ALOX5AP* may be associated with the development of ICH in Korean population \[[@B43]\].

The *APOE* gene polymorphisms are associated with many other diseases. A meta-analysis showed that *APOE* ϵ4 allele appeared to be associated with a higher prevalence of dementia in Parkinson disease \[[@B44]\]. A meta-analysis suggested that the *APOE* ϵ4 isoform was a genetic factor that might influence the age at onset of temporal lobe epilepsy \[[@B45]\]. A meta-analysis showed that the *APOE* ϵ4 allele was associated with an increased risk of developing hypertension \[[@B46]\]. A meta-analysis found that the *APOE* ϵ4 allele was associated with a moderately increased risk for progression from mild cognitive impairment to Alzheimer\'s disease-type dementia \[[@B47]\]. Prevalence of *APOE* ϵ4 alleles was significantly higher in patients with coronary artery disease than controls \[[@B48]\].

The exact mechanism of the association between *APOE* polymorphism and the risk of ICH remains unclear. *APOE* plays a critical role in redistributing lipids among central nervous system cells for normal lipid homeostasis \[[@B49]\], repairing injured neurons \[[@B50]\], maintaining synaptodendritic connections \[[@B51]\], neurite outgrowth \[[@B52]\], synaptic plasticity \[[@B53]\], mitochondrial resistance to oxidative stress \[[@B54]\], and glucose use by neurons and glial cells \[[@B25]\]. Compared with ϵ3/ϵ3, ϵ4 allele-containing genotypes are associated with increased total cholesterol levels \[[@B13]\]. It appears that the ϵ4 allele enhances amyloid deposition in blood vessels \[[@B55]\]. Thus, one might expect ϵ4 carriers to have increased susceptibility to ICH, especially in a lobar location. Furthermore, *APOE* ϵ4 allele was also associated with an increased risk of developing hypertension \[[@B46]\], which may be the reason that *APOE* ϵ4 allele was associated with a higher risk of ICH.

Several limitations of our meta-analysis should be noted. First of all, meta-analysis is powerful but also controversial-controversial because several conditions are critical to a sound meta-analysis, and small violations of those conditions can lead to misleading results \[[@B56]\]. Second, relatively small sample size of studies in overall comparisons was observed in this meta-analysis. The results of small meta-analyses should be regarded with caution, even if the *P* value shows extreme statistical significance \[[@B57]\]. Thirdly, because of the lack of individual patient data, we could not perform an adjustment estimate. In spite of these limitations, our meta-analysis also had some advantages. First, the major strengths of the meta-analysis are that we used a comprehensive searching strategy based on computer-assisted and manual searching which allowed the eligible studies to be included as far as possible. Second, no heterogeneity or publication bias was found, which leads to a possibly robust result.

In conclusion, our meta-analysis suggested that *APOE* ϵ4 allele was associated with a higher risk of ICH. Future studies will be required to clarify the biological implications of our findings.
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